| Treatment Group | |
---|---|---|
Week 52 | Rosiglitazone | Placebo |
(mm 3 ) | (N = 25) | (N = 29) |
Number with baseline and week 52 CMR scans | 21 | 26 |
Baseline (mean ± SD) | 1354 ± 532 | 1146 ± 550 |
End of treatment (mean ± SD) | 1348 ± 531 | 1134 ± 523 |
Change from baseline | Â | Â |
   mean ± SD | -5.7 ± 79.4 | -12.1 ± 104.6 |
Model adjusted change from baseline1 | Â | Â |
   mean ± SE | 12.7 ± 22.8 | -2.9 ± 20.9 |
Difference from placebo1 | Â | Â |
   mean | 15.7 | - |
   95% CI | -39.5, 70.9 | - |
   P-value | 0.57 | - |